GlassScriptPhysician profile
Dania Acebo
NPI 1386779486
$3,811.47
in general payments reported to CMS, 2019-2025
22 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,184 · 2022: $720 · 2023: $932 · 2024: $720 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,907.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $560.06 | 2021-2025 | Mounjaro, Jardiance, Kisunla |
| Galderma Laboratories, L.P. | $492.79 | 2021-2025 | |
| Amgen INC. | $410.97 | 2023-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $330.67 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $272.29 | 2021-2025 | Xifaxan, Trulance |
| Kowa Pharmaceuticals America, INC. | $244.02 | 2021-2025 | Zoryve, Seglentis |
| Novo Nordisk INC | $230.89 | 2021-2024 | Ozempic, Rybelsus |
| Azurity Pharmaceuticals, INC. | $211.21 | 2023-2024 | Edarbi, Edarbi, Adthyza |
| Exact Sciences Corporation | $181.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $154.06 | 2021-2024 | Farxiga |
| Pfizer INC. | $138.14 | 2021-2023 | |
| Abbvie INC. | $105.14 | 2021-2024 | Botox |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.64 | 2021-2023 | Synjardy, Jardiance |
| Ibsa Pharma INC. | $73.56 | 2022-2023 | Tirosint, Licart |
| Alnylam Pharmaceuticals INC. | $63.52 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $55.72 | 2021-2023 | Unithroid |
| Idorsia Pharmaceuticals US INC | $44.00 | 2023 | Quviviq |
| Amarin Pharma, INC. | $42.52 | 2021-2022 | |
| Acella Pharmaceuticals, LLC | $38.08 | 2023-2024 | NP Thyroid 60 |
| Merz North America, INC. | $32.61 | 2022 | |
| Arbor Pharmaceuticals, INC. | $31.79 | 2021-2022 | |
| Halozyme INC | $20.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dania Acebo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.